DLH(DLHC) - 2025 Q4 - Earnings Call Presentation

Financial Performance - Q4 FY2025 - Revenue for Q4 FY25 was $81.2 million, compared to $96.4 million in Q4 FY24[15] - EBITDA for Q4 FY25 was $6.6 million, compared to $10.7 million in Q4 FY24[15] - Free Cash Flow for Q4 FY25 was $10.7 million, compared to $12.2 million in Q4 FY24[15] Financial Performance - Full Year FY2025 - Revenue for FY25 was $344.5 million, compared to $395.9 million in FY24[18] - EBITDA for FY25 was $23.0 million, compared to $42.0 million in FY24[18] - Free Cash Flow for FY25 was $34.0 million, compared to $26.5 million in FY24[18] Debt and Capital Allocation - Total debt was reduced by $10.7 million in Q4 to $131.6 million[9, 20] - Mandatory term debt is paid through September 30, 2026, a year ahead of schedule[9, 22] Strategic Updates - DLH received CMMC Level 2 certification, positioning the company for high-value business in defense markets[9] - DLH was awarded an NIH Office of Information Technology contract[9]